Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
8 May 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Feb 24
424B5
Prospectus supplement for primary offering
31 Jan 24
8-K
Other Events
31 Jan 24
424B5
Prospectus supplement for primary offering
30 Jan 24
8-K
Departure of Directors or Certain Officers
28 Nov 23
8-K
Entry into a Material Definitive Agreement
27 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
6 Nov 23
8-K
Entry into a Material Definitive Agreement
16 Oct 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
8-K
Entry into a Material Definitive Agreement
7 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
424B5
Prospectus supplement for primary offering
20 Apr 23
8-K
Other Events
19 Apr 23
424B5
Prospectus supplement for primary offering
17 Apr 23
8-K
Other Events
17 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Mar 23
424B5
Prospectus supplement for primary offering
27 Feb 23
8-K
Other Events
27 Feb 23
S-8
Registration of securities for employees
27 Feb 23
10-K
2022 FY
Annual report
27 Feb 23
8-K
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
27 Feb 23
S-3ASR
Automatic shelf registration
22 Dec 22
8-K
Entry into a Material Definitive Agreement
20 Dec 22
8-K
Departure of Directors or Certain Officers
12 Dec 22
8-K
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
7 Nov 22
Latest ownership filings
4
Mikhail Eydelman
3 May 24
4
Jim Wassil
3 May 24
4
GRANT PICKERING
3 May 24
144
Notice of proposed sale of securities
1 May 24
144
Notice of proposed sale of securities
1 May 24
144
Notice of proposed sale of securities
1 May 24
4
GRANT PICKERING
25 Apr 24
144
Notice of proposed sale of securities
23 Apr 24
4
ANDREW GUGGENHIME
22 Apr 24
4
Jim Wassil
19 Apr 24
144
Notice of proposed sale of securities
18 Apr 24
4
Mikhail Eydelman
3 Apr 24
4
Jim Wassil
3 Apr 24
4
GRANT PICKERING
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
GRANT PICKERING
27 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
4
ANDREW GUGGENHIME
20 Mar 24
4
Jim Wassil
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
GRANT PICKERING
13 Mar 24
4
Jim Wassil
4 Mar 24
4
Elvia Cowan
4 Mar 24
4
Mikhail Eydelman
4 Mar 24
4
ANDREW GUGGENHIME
4 Mar 24
4
GRANT PICKERING
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
GRANT PICKERING
27 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
144
Notice of proposed sale of securities
23 Feb 24
4
ANDREW GUGGENHIME
22 Feb 24
4
Jim Wassil
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24